Osaka and Tokyo (Japan), July 7, 2017 - Maruho Co., Ltd ('Maruho', Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. ('Astellas'; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka) announce that from October 1, 2017, Maruho will succeed the marketing approval in Japan from Astellas, for anti-atopic dermatitis agent ProtopicOintment 0.1% and ProtopicOintment 0.03% for Pediatric (INN: tacrolimus hydrate, hereinafter referred to as 'ProtopicOintment').

ProtopicOintment was first approved in Japan in June 1999 with its anti-inflammatory action as a therapeutic agent for atopic dermatitis and launched in Japan in November 1999 by Fujisawa Pharmaceutical Co., Ltd. (currently Astellas). It is currently used in over 75 countries worldwide*. Maruho was assigned detailing/promotional activities in Japan for ProtopicOintment in April 2011. Distribution rights in Japan for ProtopicOintment were transferred to Maruho in April 2014. From October 2017, Maruho will provide and collect information as the manufacturer and distributor of ProtopicOintment in Japan and will ensure a stable supply of this product.

*Transferred to LEO Pharma A/S outside Japan

As a pharmaceutical company specializing in dermatology, Maruho hopes to further contribute to patients suffering from atopic dermatitis through the succession of marketing approval for Protopic Ointment.

Astellas Pharma Inc. published this content on 07 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 07 July 2017 02:10:06 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/detail/maruho-succeeds-marketing-appr.html

Public permalinkhttp://www.publicnow.com/view/4607DA7663E2AF1FE50345A78FBA7BE0739598F0